BriaCell reports OS data from Phase 2 study of Bria-IMT in breast cancer

BriaCell Therapeutics announced overall survival data of its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor in late stage metastatic breast cancer. Median overall survival of 15.6 months is reported in BriaCell’s most recent patients vs. 6.7-9.3 months for similar patients reported in the literature. These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer and represent patients enrolled post-COVID when full study activities resumed. This represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023. The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed. This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023.